| 1 |
Chakraborty R, Sharma D, Kapoor DU, Dwivedi A, Khabiya R, Sen S. Implications of metabolic dysfunction associated fatty liver disease in COVID-19. World J Clin Cases 2023; 11(6): 1275-1286 [DOI: 10.12998/wjcc.v11.i6.1275] [Reference Citation Analysis]
|
| 2 |
Jeeyavudeen MS, Chaudhari R, Pappachan JM, Fouda S. Clinical implications of COVID-19 in patients with metabolic-associated fatty liver disease. World J Gastroenterol 2023; 29(3): 487-502 [PMID: 36688018 DOI: 10.3748/wjg.v29.i3.487] [Reference Citation Analysis]
|
| 3 |
Akhmedov VA. A new challenge for the liver in the 21st century. jour 2023. [DOI: 10.31146/1682-8658-ecg-206-10-163-168] [Reference Citation Analysis]
|
| 4 |
Naeem M, Bano N, Manzoor S, Ahmad A, Munawar N, Razak SIA, Lee TY, Devaraj S, Hazafa A. Pathogenetic Mechanisms of Liver-Associated Injuries, Management, and Current Challenges in COVID-19 Patients. Biomolecules 2023;13. [PMID: 36671484 DOI: 10.3390/biom13010099] [Reference Citation Analysis]
|
| 5 |
Karlafti E, Paramythiotis D, Pantazi K, Georgakopoulou VE, Kaiafa G, Papalexis P, Protopapas AA, Ztriva E, Fyntanidou V, Savopoulos C. Drug-Induced Liver Injury in Hospitalized Patients during SARS-CoV-2 Infection. Medicina (Kaunas) 2022;58. [PMID: 36557050 DOI: 10.3390/medicina58121848] [Reference Citation Analysis]
|
| 6 |
Lin K, Gausman V, Poles M, Popov V. Acute Liver Failure Secondary to Remdesivir in the Treatment of COVID-19. ACG Case Rep J 2022;9:e00866. [PMID: 36212242 DOI: 10.14309/crj.0000000000000866] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 7 |
Kumar S, Singla B, Singh AK, Thomas-gooch SM, Zhi K, Singh UP. Hepatic, Extrahepatic and Extracellular Vesicle Cytochrome P450 2E1 in Alcohol and Acetaminophen-Mediated Adverse Interactions and Potential Treatment Options. Cells 2022;11:2620. [DOI: 10.3390/cells11172620] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 8 |
Huang J, Zhang Z, Hao C, Qiu Y, Tan R, Liu J, Wang X, Yang W, Qu H. Identifying Drug-Induced Liver Injury Associated With Inflammation-Drug and Drug-Drug Interactions in Pharmacologic Treatments for COVID-19 by Bioinformatics and System Biology Analyses: The Role of Pregnane X Receptor. Front Pharmacol 2022;13:804189. [DOI: 10.3389/fphar.2022.804189] [Reference Citation Analysis]
|
| 9 |
Chen H, Chen Q. COVID-19 Pandemic: Insights into Interactions between SARS-CoV-2 Infection and MAFLD. Int J Biol Sci 2022;18:4756-67. [PMID: 35874945 DOI: 10.7150/ijbs.72461] [Reference Citation Analysis]
|
| 10 |
Budhraja A, Basu A, Gheware A, Abhilash D, Rajagopala S, Pakala S, Sumit M, Ray A, Subramaniam A, Mathur P, Nambirajan A, Kumar S, Gupta R, Wig N, Trikha A, Guleria R, Sarkar C, Gupta I, Jain D. Molecular signature of postmortem lung tissue from COVID-19 patients suggests distinct trajectories driving mortality. Dis Model Mech 2022;15:dmm049572. [PMID: 35438176 DOI: 10.1242/dmm.049572] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 11 |
Teschke R, Méndez-Sánchez N, Eickhoff A. Liver Injury in COVID-19 Patients with Drugs as Causatives: A Systematic Review of 996 DILI Cases Published 2020/2021 Based on RUCAM as Causality Assessment Method. Int J Mol Sci 2022;23:4828. [PMID: 35563242 DOI: 10.3390/ijms23094828] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 12 |
Gabrielli M, Franza L, Esperide A, Gasparrini I, Gasbarrini A, Franceschi F; on behalf of GEMELLI AGAINST COVID 2019. Liver Injury in Patients Hospitalized for COVID-19: Possible Role of Therapy. Vaccines 2022;10:192. [DOI: 10.3390/vaccines10020192] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 13 |
Massart J, Begriche K, Corlu A, Fromenty B. Xenobiotic-Induced Aggravation of Metabolic-Associated Fatty Liver Disease. IJMS 2022;23:1062. [DOI: 10.3390/ijms23031062] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
|
| 14 |
Hu X, Sun L, Guo Z, Wu C, Yu X, Li J. Management of COVID-19 patients with chronic liver diseases and liver transplants. Ann Hepatol 2022;27:100653. [PMID: 34929350 DOI: 10.1016/j.aohep.2021.100653] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 15 |
Ferron PJ, Le Daré B, Bronsard J, Steichen C, Babina E, Pelletier R, Hauet T, Morel I, Tarte K, Reizine F, Clément B, Fromenty B, Gicquel T. Molecular Networking for Drug Toxicities Studies: The Case of Hydroxychloroquine in COVID-19 Patients. Int J Mol Sci 2021;23:82. [PMID: 35008505 DOI: 10.3390/ijms23010082] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 16 |
Budhraja A, Basu A, Gheware A, Abhilash D, Rajagopala S, Pakala S, Sumit M, Ray A, Arulselvi S, Mathur P, Nambirajan A, Kumar S, Gupta R, Wig N, Trikha A, Guleria R, Sarkar C, Gupta I, Jain D. Molecular signature of postmortem lung tissue from COVID-19 patients suggests distinct trajectories driving mortality.. [DOI: 10.1101/2021.11.08.467705] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 17 |
Kolaric TO, Nincevic V, Kuna L, Duspara K, Bojanic K, Vukadin S, Raguz-Lucic N, Wu GY, Smolic M. Drug-induced Fatty Liver Disease: Pathogenesis and Treatment. J Clin Transl Hepatol 2021;9:731-7. [PMID: 34722188 DOI: 10.14218/JCTH.2020.00091] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 18 |
Trukhan DI, Davydov EL. Liver drug damage: possibilities of polyionic succinate-methioninic complex during the pandemic of new coronavirus infection (COVID-19). Medicinskij sovet 2021. [DOI: 10.21518/2079-701x-2021-15-110-121] [Reference Citation Analysis]
|
| 19 |
Vitrone M, Mele F, Durante-Mangoni E, Zampino R. Drugs and liver injury: a not to be overlooked binomial in COVID-19. J Chemother 2021;:1-14. [PMID: 34644236 DOI: 10.1080/1120009X.2021.1988203] [Reference Citation Analysis]
|
| 20 |
Yanlan Xu, Xinyu Yang, Hua Bian, Mingfeng Xia. Metabolic dysfunction associated fatty liver disease and coronavirus disease 2019: clinical relationship and current management. Lipids Health Dis 2021;20:126. [PMID: 34602072 DOI: 10.1186/s12944-021-01564-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 21 |
Vranić L, Radovan A, Poropat G, Mikolašević I, Milić S. Non-Alcoholic Fatty Liver Disease and COVID-19-Two Pandemics Hitting at the Same Time. Medicina (Kaunas) 2021;57:1057. [PMID: 34684094 DOI: 10.3390/medicina57101057] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 22 |
Mikolasevic I, Bozic D, Pavić T, Ruzic A, Hauser G, Radic M, Radic-Kristo D, Razov-Radas M, Puljiz Z, Milic S. Liver disease in the era of COVID-19: Is the worst yet to come? World J Gastroenterol 2021; 27(36): 6039-6052 [PMID: 34629818 DOI: 10.3748/wjg.v27.i36.6039] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 23 |
Delgado A, Stewart S, Urroz M, Rodríguez A, Borobia AM, Akatbach-Bousaid I, González-Muñoz M, Ramírez E. Characterisation of Drug-Induced Liver Injury in Patients with COVID-19 Detected by a Proactive Pharmacovigilance Program from Laboratory Signals. J Clin Med 2021;10:4432. [PMID: 34640458 DOI: 10.3390/jcm10194432] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 24 |
Su YJ, Chang CW, Chen MJ, Lai YC. Impact of COVID-19 on liver. World J Clin Cases 2021;9:7998-8007. [PMID: 34621856 DOI: 10.12998/wjcc.v9.i27.7998] [Reference Citation Analysis]
|
| 25 |
Su YJ, Chang CW, Chen MJ, Lai YC. Impact of COVID-19 on liver. World J Clin Cases 2021; 9(27): 7998-8007 [PMID: 34621856 DOI: 10.12998/wjcc.v9.i27.7998] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 26 |
Vargas-Mendoza N, García-Machorro J, Angeles-Valencia M, Martínez-Archundia M, Madrigal-Santillán EO, Morales-González Á, Anguiano-Robledo L, Morales-González JA. Liver disorders in COVID-19, nutritional approaches and the use of phytochemicals. World J Gastroenterol 2021;27:5630-65. [PMID: 34629792 DOI: 10.3748/wjg.v27.i34.5630] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 27 |
Zhai G, Li M, Wang Y, Wu J. Drug-Induced Liver Disturbance During the Treatment of COVID-19. Front Pharmacol 2021;12:719308. [PMID: 34483929 DOI: 10.3389/fphar.2021.719308] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 28 |
Gracia-Ramos AE, Jaquez-Quintana JO, Contreras-Omaña R, Auron M. Liver dysfunction and SARS-CoV-2 infection. World J Gastroenterol 2021; 27(26): 3951-3970 [PMID: 34326607 DOI: 10.3748/wjg.v27.i26.3951] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 29 |
Al-Nimer MS. Is COVID-19-induced liver injury different from other RNA viruses? World J Meta-Anal 2021; 9(2): 108-127 [DOI: 10.13105/wjma.v9.i2.108] [Reference Citation Analysis]
|
| 30 |
Adenote A, Dumic I, Madrid C, Barusya C, Nordstrom CW, Rueda Prada L. NAFLD and Infection, a Nuanced Relationship. Can J Gastroenterol Hepatol 2021;2021:5556354. [PMID: 33977096 DOI: 10.1155/2021/5556354] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
|
